Editorial. Refers to a study published in the same issue by Freedberg and colleagues that helps place the cost of opportunistic infection prophylaxis in perspective. The advances in opportunistic infection prophylaxis and highly active antiretroviral therapy and intervention to prevent transmission of human immunodeficiency virus (HIV) infection; The importance in demonstrating that expensive acquired immune deficiency syndrome (AIDS) therapies